CORESTEM Inc (166480) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.103x

Based on the latest financial reports, CORESTEM Inc (166480) has a cash flow conversion efficiency ratio of -0.103x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-4.18 Billion ≈ $-2.83 Million USD) by net assets (₩40.62 Billion ≈ $27.53 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see CORESTEM Inc stock valuation for the company's overall valuation and market capitalisation.

CORESTEM Inc - Cash Flow Conversion Efficiency Trend (2014–2024)

This chart illustrates how CORESTEM Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.

CORESTEM Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of CORESTEM Inc ranked by their cash flow conversion efficiency. Explore CORESTEM Inc cash earnings quality to measure how well operating cash flow supports reported net income.

Company Cash Flow Conversion Efficiency
Development Advance Solution Co Ltd
KO:058730
0.022x
CLEAN TEQ WATER LTD
F:9NK
N/A
CLOUDR GROUP LTD.
F:H3L
N/A
SANGBO Corp
KQ:027580
-0.080x
Ta Jiang Co Ltd
TW:1453
-0.077x
ENERGY S.P.A.
F:S2I
N/A
Immutep Ltd
AU:IMM
-0.233x
HARMONEY CORP. LTD
F:6DR
N/A

Annual Cash Flow Conversion Efficiency for CORESTEM Inc (2014–2024)

The table below shows the annual cash flow conversion efficiency of CORESTEM Inc from 2014 to 2024. View 166480 live share price for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 ₩48.59 Billion
≈ $32.93 Million
₩-21.12 Billion
≈ $-14.31 Million
-0.435x +45.73%
2023-12-31 ₩19.60 Billion
≈ $13.28 Million
₩-15.70 Billion
≈ $-10.64 Million
-0.801x -294.34%
2022-12-31 ₩41.46 Billion
≈ $28.10 Million
₩-8.42 Billion
≈ $-5.71 Million
-0.203x +1.23%
2021-12-31 ₩37.19 Billion
≈ $25.20 Million
₩-7.65 Billion
≈ $-5.18 Million
-0.206x -290.05%
2020-12-31 ₩41.29 Billion
≈ $27.98 Million
₩4.47 Billion
≈ $3.03 Million
0.108x +1260.00%
2019-12-31 ₩57.70 Billion
≈ $39.10 Million
₩-538.08 Million
≈ $-364.65K
-0.009x +48.55%
2018-12-31 ₩62.24 Billion
≈ $42.18 Million
₩-1.13 Billion
≈ $-764.48K
-0.018x +81.10%
2017-12-31 ₩65.60 Billion
≈ $44.46 Million
₩-6.29 Billion
≈ $-4.26 Million
-0.096x -282.69%
2016-12-31 ₩66.73 Billion
≈ $45.22 Million
₩3.50 Billion
≈ $2.37 Million
0.053x +424.60%
2015-12-31 ₩63.04 Billion
≈ $42.72 Million
₩-1.02 Billion
≈ $-691.01K
-0.016x +87.47%
2014-12-31 ₩18.97 Billion
≈ $12.86 Million
₩-2.45 Billion
≈ $-1.66 Million
-0.129x --

About CORESTEM Inc

KQ:166480 Korea Biotechnology
Market Cap
$39.60 Million
₩58.44 Billion KRW
Market Cap Rank
#22863 Global
#1511 in Korea
Share Price
₩2080.00
Change (1 day)
-1.42%
52-Week Range
₩1060.00 - ₩4800.00
All Time High
₩32150.00
About

CORESTEMCHEMON Inc., a bio-pharmaceutical company, engages in the development and production of stem cell therapies for the treatment of incurable diseases in South Korea. It offers NEURONATA-R inj, an autologous bone marrow mesenchymal stem cell therapy for the treatment of amyotrophic lateral sclerosis (ALS). The company also engages in the development of various therapy products for the treatm… Read more